New Leadership Presents “Good Opportunity” to Expand Community-Based Trials

Commentary
Video

START is the largest early-phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, PhD, MRCPI.

In a conversation with CancerNetwork®, Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, spoke about her new appointment as the principal investigator and director of clinical research at the Northwell Health unit of the Southern Texas Accelerated Research Therapeutics (START) Center for Cancer Research. Following a strategic partnership formed between Northwell Health and START in May 2024, Coyne will oversee early-phase clinical trials at New York’s first START research site at the R.J. Zuckerberg Cancer Center in New Hyde Park.

According to Coyne, the new position has offered her a “moment of delight” as well as an opportunity to expand clinical trial enrollment among patients with cancer who reside in community settings. Additionally, she highlighted the history behind START’s formation, which she described as the largest early-phase oncology network in the community setting.

Transcript:

It has truly been a moment of delight for me and one that has been a proud moment, personally. It is, however, incredibly humbling to have been offered this opportunity, one that I am looking forward to putting in all my efforts [and] making this, hopefully, a good opportunity for patients to be able to be considered for trials within the community [while] partnering, in this sense, with Northwell Health here at their Long Island campus.

START stands for Southern Texas Accelerated Research Therapeutics, and it was founded in 2007 by a group of oncologists in the locality that were interested in [bringing] these types of trials into their community. START, since then, has had an increasingly well-recognized record both in the US as well as in Europe. It is now the largest early-phase oncology network in the community, globally. This is by a variety of metrics, including the number of physicians that are dedicated [to] START, principal investigators or PIs, as well as the extent and the locality of the START networks to date.

Reference

Olt B. Northwell names Geraldine O’Sullivan Coyne, MD, PhD, to lead clinical trials at new START center. News release. Northwell Health. July 22, 2025. Accessed August 7, 2025. https://tinyurl.com/bdcua8ck

Recent Videos
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.